Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Pulse Biosciences, Inc.

pulsebiosciences.com
Filed: Mar 23, 2026CIK: 0001625101Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Pulse Biosciences awarded Chief Technology Officer Darrin R. Uecker 100,000 restricted stock units vesting over three years, recognizing his leadership in atrial fibrillation product development and signaling the company's commitment to retaining key technical talent.

Key Takeaways

CTO Darrin R. Uecker received 100,000 RSUs with a three-year vesting schedule, indicating confidence in his continued leadership

The award recognizes specific contributions to atrial fibrillation product development, a key therapeutic focus for the company

2 more takeaways

Related Filings (9)

9 more filings from Pulse Biosciences, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 23, 2026
Item5.02
CategoryExecutive Change
CIK0001625101
Accession #plse20260327_8k.htm
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
leadership transitionmaterial agreement

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings